For distributors, clinical laboratories, and molecular diagnostics companies, sourcing a lung cancer genetic testing panel is a procurement decision as much as a scientific one. A 73-gene panel strikes a practical middle ground between small hotspot panels and whole-exome sequencing: broad enough to cover actionable driver mutations, yet targeted enough to keep turnaround time and cost predictable. This guide walks buyers through the operational realities—sample handling, turnaround time, batch stability, and minimum order quantities.
Panels of this size typically span actionable biomarkers that guide therapy: EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK, and HER2, alongside immunotherapy and resistance genes. The design captures single-nucleotide variants, insertions/deletions, and copy number changes most acted upon in practice. Request a full gene list and variant-classification rules before purchase, so the panel's utility matches the population your laboratory serves.
The same panel must support different sample inputs. Solid tissue—FFPE blocks or slides—remains the diagnostic standard, but low tumor cellularity can compromise detection. Liquid biopsy using circulating tumor DNA (ctDNA) from plasma offers a non-invasive alternative, but needs high-sensitivity chemistry and stricter pre-analytical handling. Confirm the panel and reagents are validated for both FFPE and plasma, because extraction, library preparation, and analysis differ.
Patients and oncologists wait days for results that determine whether to start targeted therapy. Turnaround is driven by library prep chemistry, instrument availability, and the bioinformatics pipeline. Verify the promised window—typically a few days for a well-optimized NGS workflow—and confirm whether the supplier provides analysis software, reference files, and variant callers as part of the package. A turnkey solution avoids assembling components from multiple vendors.
For a laboratory running consistent volumes, batch-to-batch consistency is critical; reagents that drift between lots force revalidation and add cost. Ask about lot traceability, quality-control release data, and whether a reference standard ships with each kit. Long shelf-life and stable cold-chain logistics reduce waste, and buffer stock protects you from shortages.
Minimum order quantity is where procurement meets economics. A low MOQ lowers entry risk for a laboratory still validating the assay, while a higher MOQ usually commands better unit pricing and security of supply. Negotiate a tiered structure: a modest initial order for validation, then volume pricing once the assay is routine. Clarify lead times, replacement policy for defective lots, and support response windows.
Q: Can the same 73-gene panel process both FFPE tissue and plasma samples? A: Most modern panels are validated for both, but confirm this explicitly. Tissue and liquid biopsy use different extraction methods and detection sensitivities.
Q: What is the typical turnaround time for this panel? A: It varies by workflow, but a well-optimized NGS pipeline typically returns results in a few business days. Confirm the promised window and whether analysis software is included.
Q: Does the supplier provide bioinformatics and analysis software? A: Some do, and others do not. A turnkey package including variant callers, reference files, and reporting tools reduces integration work, so clarify this in the quote.
Q: How do I manage batch variability when scaling up testing volume? A: Ask for lot traceability, QC release data, and a shipped reference standard with each batch. Negotiate a tiered MOQ so you can validate a small lot first, then scale with volume pricing.
For distributors, clinical laboratories, and molecular diagnostics companies, sourcing a lung cancer genetic testing panel is a procurement decision as much as a scientific one. A 73-gene panel strikes a practical middle ground between small hotspot panels and whole-exome sequencing: broad enough to cover actionable driver mutations, yet targeted enough to keep turnaround time and cost predictable. This guide walks buyers through the operational realities—sample handling, turnaround time, batch stability, and minimum order quantities.
Panels of this size typically span actionable biomarkers that guide therapy: EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK, and HER2, alongside immunotherapy and resistance genes. The design captures single-nucleotide variants, insertions/deletions, and copy number changes most acted upon in practice. Request a full gene list and variant-classification rules before purchase, so the panel's utility matches the population your laboratory serves.
The same panel must support different sample inputs. Solid tissue—FFPE blocks or slides—remains the diagnostic standard, but low tumor cellularity can compromise detection. Liquid biopsy using circulating tumor DNA (ctDNA) from plasma offers a non-invasive alternative, but needs high-sensitivity chemistry and stricter pre-analytical handling. Confirm the panel and reagents are validated for both FFPE and plasma, because extraction, library preparation, and analysis differ.
Patients and oncologists wait days for results that determine whether to start targeted therapy. Turnaround is driven by library prep chemistry, instrument availability, and the bioinformatics pipeline. Verify the promised window—typically a few days for a well-optimized NGS workflow—and confirm whether the supplier provides analysis software, reference files, and variant callers as part of the package. A turnkey solution avoids assembling components from multiple vendors.
For a laboratory running consistent volumes, batch-to-batch consistency is critical; reagents that drift between lots force revalidation and add cost. Ask about lot traceability, quality-control release data, and whether a reference standard ships with each kit. Long shelf-life and stable cold-chain logistics reduce waste, and buffer stock protects you from shortages.
Minimum order quantity is where procurement meets economics. A low MOQ lowers entry risk for a laboratory still validating the assay, while a higher MOQ usually commands better unit pricing and security of supply. Negotiate a tiered structure: a modest initial order for validation, then volume pricing once the assay is routine. Clarify lead times, replacement policy for defective lots, and support response windows.
Q: Can the same 73-gene panel process both FFPE tissue and plasma samples? A: Most modern panels are validated for both, but confirm this explicitly. Tissue and liquid biopsy use different extraction methods and detection sensitivities.
Q: What is the typical turnaround time for this panel? A: It varies by workflow, but a well-optimized NGS pipeline typically returns results in a few business days. Confirm the promised window and whether analysis software is included.
Q: Does the supplier provide bioinformatics and analysis software? A: Some do, and others do not. A turnkey package including variant callers, reference files, and reporting tools reduces integration work, so clarify this in the quote.
Q: How do I manage batch variability when scaling up testing volume? A: Ask for lot traceability, QC release data, and a shipped reference standard with each batch. Negotiate a tiered MOQ so you can validate a small lot first, then scale with volume pricing.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
